Trials / Completed
CompletedNCT02337205
Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis
A Phase 1, Single-Center, Safety, Tolerability, and Pharmacokinetic Study of KX2 391 Ointment in Subjects With Actinic Keratosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Athenex, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1 study to access the safety and tolerability of KX2-391 ointment in subjects who have Actinic Keratosis. This study will also access the amount of KX2-391 drug that enters the blood stream through dermal application of the ointment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KX2-391 Ointment | KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period. |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2015-01-13
- Last updated
- 2018-07-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02337205. Inclusion in this directory is not an endorsement.